Immune Pharmaceuticals Inc. Trading Symbol is Now IMNP on Both NASDAQ OMX Stockholm Exchange and OTCQX Trading Platform

TARRYTOWN, New York, Sept. 23, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange: IMNP and OTCQX: IMNP, formerly EPCTD) announced today that effective September 23, 2013 the Company's symbol for its common stock trading on the OTCQX trading platform will change to "IMNP". The Company's common stock had been required to trade under the symbol "EPCTD" since August 21, 2013 as a result of the previously implemented 1-for-40 reverse stock split. The Company's common stock has been trading on the NASDAQ OMX Stockholm Exchange under the symbol "IMNP" since August 21, 2013, so as a result of this most recent change the Company's common stock will be trading under the same symbol in all of its trading markets.

Dr. Daniel G. Teper, the Company's Chairman and Chief Executive Officer, commented, "This change now aligns Immune's trading symbol on the OTCQX with our symbol on the NASDAQ OMX Stockholm Exchange, enabling our investors to easily identify the Company and track our progress as we achieve new clinical and business development milestones."

On August 26, 2013, Immune Pharmaceuticals announced the completion of the merger of Immune Pharmaceuticals Ltd. and EpiCept Corporation, forming a company focused on the development of antibody therapeutics, including bertilimumab, which is in Phase II clinical development for ulcerative colitis and bullous pemphigoid, an orphan auto-immune indication, and NanomAbs®, a platform of antibody targeted nanoparticles for cancer treatment.

About Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange: IMNP; OTCQX: IMNP, formerly EPCTD) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer.  The Company's lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn's disease and severe asthma.  The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells.  The Company's growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors.

Immune is headquartered in Tarrytown, New York, with its primary research and development facilities in Israel. 

For more information, visit Immune's website at www.immunepharmaceuticals.com.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal" or the negative of those words or other comparable words to be uncertain and forward-looking.  Such forward-looking statements include statements that express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that clinical trials for bertilimumab, crolibulin or AmiKet™ will not be successful; the risk that bertilimumab, crolibulin, AmiKet™ or compounds arising from our NanomAb® program will not receive regulatory approval or achieve significant commercial success; the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet™ on attractive terms, a timely basis or at all; the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials; the risk that we will not obtain approval to market any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings which are available at www.sec.gov or at www.immunepharmaceuticals.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.

EPCTD-GEN